Zoetis Launches Portela® (relfovetmab) in Canada and the European Union
Business Wire•22/07/2026•07:30 ET
3
Whiz Insights
Zoetis Launches Portela(®) (relfovetmab) in Canada and the European Union
First long-acting anti-NGF monoclonal antibody therapy for cats offers three months of osteoarthritis pain relief with a single injection
Get started
Create a free account to read the full story.